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Abstract
Respiratory syncytial virus (RSV) is a major cause of severe lower respiratory tract disease in infancy and early childhood.
Despite its importance as a pathogen, there is no licensed vaccine to prevent RSV infection. The G glycoprotein of RSV, a
major attachment protein, is a potentially important target for protective antiviral immune responses and has been shown
to exhibit chemotactic activity through CX3C mimicry. Here, we show that sublingual or intranasal immunization of a
purified G protein fragment of amino acids from 131 to 230, designated Gcf, induces strong serum IgG and mucosal IgA
responses. Interestingly, these antibody responses could be elicited by Gcf even in the absence of any adjuvant, indicating a
novel self-adjuvanting property of our vaccine candidate. Gcf exhibited potent chemotactic activity in in vitro cell migration
assay and cysteine residues are necessary for chemotactic activity and self-adjuvanticity of Gcf in vivo. Mucosal
immunization with Gcf also provides protection against RSV challenge without any significant lung eosinophilia or vaccine-
induced weight loss. Together, our data demonstrate that mucosal administration of Gcf vaccine elicits beneficial protective
immunity and represents a promising vaccine regimen preventing RSV infection.
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Introduction
Respiratory syncytial virus (RSV) is the leading cause of serious
respiratory tract disease in infants and young children worldwide.
RSV is also an important viral pathogen of lower respiratory tract
illness in immunocompromised patients and the elderly [1,2,3].
Despite the importance of RSV as a respiratory pathogen, there is
no licensed vaccine currently available. Thus, development of an
effective and safe RSV vaccine is urgently required.
The RSV glycoprotein (G) was identified as the major RSV
attachment protein [4], and is thought to be important for protection
against RSV infection [5]. The RSV G protein contains a CX3C
motif at amino acids 182 to 186 in the central conserved region and
binds to CX3CR1, inducing leukocyte chemotaxis [6]. Numerous
studies have suggested that immunization ofRSV Gis associated with
the induction of polarized Th2 type responses which leads to
pulmonary eosinophilia upon RSV challenge of G-immunized mice
[7,8,9,10,11]. However, we have recentlyshown that singleintranasal
immunization of recombinant adenovirus expressing a fragment of
RSV G protein induces strong antibody responses without atypical
pulmonary inflammation after RSV challenge [12], demonstrating
that G protein could provide protection without enhanced lung
pathology, depending on the vehicle and/or method of delivery.
Mucosal vaccination against pathogens generally offers several
attractive advantages to conventional systemic vaccination, such as
higherlevelsofantibodiesandprotectionatthesitesofpathogenentry,
and non-invasive and convenient administration. Since mucosal
vaccinationtargetsspecificmucosalareaandmostlyinducesprotective
immunity at the site of administration, intranasal immunization is
thought to be most appropriate for vaccines against respiratory
pathogens. However, a safety issue caused by the redirection of the
vaccine to the central nerve system has remained about intranasal
administration[13,14].Incontrast,thesublingualroutehasbeenused
for allergen immunotherapy and is generally known to induce T-cell
anergy,immunedeviation,andactivationofregulatoryTcells[15,16].
However,ithasrecentlybeenshownthatsublingualadministrationof
a protein antigen with cholera toxin (CT) adjuvant can induce strong
antigen-specific antibody and CTL responses that are comparable to
those induced by intranasal administration [17].
In the present study, we targeted the RSV G protein fragment
of residues 131 to 230 as a vaccine candidate, and expressed and
purified this fragment from E. coli. We show that sublingual or
intranasal immunization of G protein fragment induces strong
serum IgG responses as well as mucosal IgA responses, and
provides potent protection against RSV challenge, even in the
absence of any adjuvant.
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Construction and purification of RSV G protein fragment,
Gcf
The human RSV G glycoprotein contains a central conserved
region that includes four completely conserved cysteine residues.
Antigenic analyses of G protein with monoclonal antibodies
suggest the importance of this region as both immunogen and an
antigen [18,19]. Based on the G protein architecture, we designed
a subunit vaccine that encompasses the neutralizing epitopes of the
central conserved region and the important structural elements.
This vaccine construct included amino acid sequences from 131 to
230 and was cloned into pET-21d expression vector; the resulting
protein was designated as Gcf (Fig. 1A). The Gcf protein was
purified from E. coli and analyzed by SDS-PAGE and western
blotting, showing a predominant band at the expected molecular
weight of ,17 kDa, corresponding to monomeric form (Fig. 1B
and C).
Humoral immune response to RSV G protein fragment
We next examined whether purified Gcf could elicit Ag-specific
immune responses in vivo. Recently, sublingual immunization was
shown to efficiently induce both mucosal and systemic antibody
responses [17]. To compare the immune responses induced by
different routes of vaccination, groups of BALB/c mice were
inoculated via sublingual (s.l.), intranasal (i.n.), or intramuscular
(i.m.) route with 20 mg of Gcf with or without adjuvant on days 0
and 14. For comparison, live RSV A2 virus was given by i.n.
instillation or formalin-inactivated RSV particle (FI-RSV) was
injected into the foot-pad, if necessary. Two weeks after each
immunization, animals were bled and the sera of individual
animals were examined for G-specific IgG by ELISA. Serum IgG
antibody responses were readily detected in all groups of immune
mice (Fig. 2A). Intramuscular injection with alum and intranasal
immunization elicited slightly higher serum IgG responses than
sublingual immunization. Intriguingly, i.n. or s.l. immunization of
Gcf alone induced significant serum IgG responses,and the
antibody response induced following vaccination by the i.n. route
was further enhanced when Gcf was given together with CT
adjuvant.
Secretory antibodies are the first line of host defense against
aerial pathogens and are known to be important correlates of
protection against RSV [20]. To examine whether Gcf vaccina-
tion also elicits mucosal antibody response in the respiratory tract,
bronchoalveolar lavage (BAL) was performed three weeks after the
second immunization and levels of specific IgA in the BAL were
determined by ELISA. As shown in Fig. 2B, the levels of mucosal
IgA were elevated in all immune groups, and the Gcf/CT i.n.
group showed the highest levels of mucosal IgA. These results
demonstrate that mucosal immunization of purified Gcf with or
without adjuvant successfully induces secretory IgA responses.
T-cell responses to G protein fragment and no enhanced
diseases
Priming of mice with FI-RSV or vaccinia virus expressing G
protein induces Th2-biased responses and enhances diseases
characterized by pulmonary eosinophilia following RSV challenge
in a mouse model [21,22]. It is thought that G-induced enhanced
disease is associated with dominant G-specific Th responses in the
absence of CTL response [11,21]. Since Gcf contains I-E
d-
restricted Th epitope, we examined whether Gcf immunization
primes G-specific CD4 T cells and subsequently induces enhanced
disease. To this end, Gcf-, FI-RSV or live RSV-immune mice
were challenged with RSV, and checked for G-specific CD4 T
cells by intracellular cytokine staining with CD44 as an activated
T-cell marker. As shown in Fig. 3, the G-specific IFN-c-producing
CD4 T-cell response was low in the lungs of s.l. Gcf-immunized
group (#1.4% of gated CD4 T cells), while slightly stronger
responses were observed in the Gcf/CT or live RSV immunized
group (,3.0% and ,2.5% of gated CD4 T cells on average,
respectively; Fig. 3A and B).
It is true that Th2-biased response by G protein priming is one
of important issues of RSV vaccine development. Thus, we
performed an experiment to check the level of Th2 type cytokines
after live RSV challenge of immunized mice. IL-4, IL-5, IL-6, IL-
10, or IL-13 levels in lung supernatants at day 5 post-challenge
were measured by multiplex antibody-based assay as described in
the Materials and Methods. The levels of IL-4, IL-5, IL-10, or IL-
13 detected in lung samples from mice immunized with FI-RSV
were statistically greater than those of mice immunized with Gcf or
Figure 1. Expression and purification of recombinant G protein fragment, Gcf. (A) Deduced amino-acid sequence of the recombinant RSV
G protein fragment (Gcf). RSV G-derived amino acids are indicated in bold letters and the conserved four cysteine residues are underlined. For
comparison, the same regions of RSV long and line 19 strains are aligned. The five regions of B-cell epitopes defined by the previous studies are
indicated by residue numbers and thick lines below the aligned sequences. The expression and purification steps of the Gcf by affinity (HisTrap) and
gel filtration chromatography (Superdex-75) was confirmed by SDS-PAGE (B) and western blotting (C) with anti-RSV polyclonal antibody under
reducing condition (+DTT) or non-reducing condition (2DTT).
doi:10.1371/journal.pone.0032226.g001
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2 cytokines were observed in Gcf or Gcf/CT immunized mice.
To determine whether the mucosal immunization of Gcf
potentiates eosinophilia, the levels of eosinophilia in BAL of the
immune mice were examined by flow cytometry five days after
challenge using antibodies directed to Siglec-F, CD45, and CD11c
as described previously [23]. A weak infiltrate of eosinophils, less
than 2% of the total CD45+ BAL cells, was observed in Gcf-
immune mice while more pronounced eosinophil influx was
detected in the Gcf/CT group (,13.1% on average, Fig. 4A and
B). The level of eosinophil influx in Gcf-immune mice was similar
in magnitude to that observed in the control mice or mice
previously injected with live RSV virus. As a positive control,
eosinophilia was markedly enhanced in FI-RSV-immune animals
(Fig. 4; ,45% of total CD45+ BAL cells). These results suggest
that mucosal Gcf immunization in the absence of adjuvant barely
increased the risk of development of vaccine-induced eosinophilia.
Protective efficacy of mucosal Gcf vaccine against RSV
challenge
Our results demonstrate that mucosal vaccination of Gcf
protein successfully induces humoral responses. To test whether
the immunity induced by mucosal Gcf vaccination confers
protection against virus challenge, the immune mice were
challenged with live RSV A2 virus at four weeks after
immunization. While there was active RSV replication in the
lungs of the control mice, s.l. or i.n. immunization of Gcf/CT
adjuvant prevented any detectable RSV replication in the lungs at
the peak of viral replication (Fig. 5). A group of mice previously
injected with FI-RSV or live RSV A2 virus also exhibited
complete protection from the challenge (data not shown). It is also
noteworthy that i.n. or s.l. immunization of Gcf alone resulted in
almost complete protection (Fig. 5). In keeping with potent lung
protection, there was no significant weight loss upon RSV
challenge in Gcf-immune mice, while FI-RSV-scarified mice
showed significant weight loss and disease scores (data not shown).
Together, these results suggest that mucosal Gcf vaccination gives
rise to protective immunity in the absence of priming of pathologic
CD4 T cells and subsequent vaccine-enhanced diseases.
Chemotactic activity of recombinant Gcf
It is interesting to note that mucosal immunization of Gcf
without any adjuvant also elicited strong humoral responses. The
core domain of G protein contains a CX3C motif that has limited
homology with the CX3C domain of the chemokine fractalkine
[6]. Since Gcf contains this CX3C motif, we examined whether
the purified Gcf exhibits chemotactic activity in an in vitro
chemotaxis assay. As a control, a mutant Gcf, GcfDCys4, was
generated in which four cysteine residues were substituted with
alanine. When THP-1 cells were incubated with wild type Gcf
and 10% FBS as a positive control [24], the numbers of migrating
cells increased ,3.5-fold and ,5-fold, respectively (Fig. 6A).
However, the mutant GcfDCys4 exhibited significantly decreased
chemotactic activity compared to wild type Gcf, indicating that
cysteine residues are necessary for Gcf-mediated chemotactic
activity.
Next, we determined whether in vivo administration of Gcf
without adjuvant recruits immune cells to the site of injection. As
shown in Fig. 6B, intranasal administration of Gcf significantly
increased infiltration of CD11c
hiCD80
+ (possibly dendritic cells),
CD11b
hiCD14
+ (macrophages), and CD3
+ (T cells and NKT cells)
cells to the lungs, while GcfDCys4 did not.
To determine whether the chemotactic activity of recombi-
nant Gcf is indeed necessary for the induction of specific
immune responses without any adjuvant, mice were i.n.
immunized with wild type Gcf or mutant GcfDCys4 alone and
antibody responses were checked. As shown in Fig. 7A, specific
serum antibody response was not detected above background in
the mutant GcfDCys4-immune group, suggesting that cysteine
residues and chemotactic activity of Gcf are required for its
immunogenicity in the absence of adjuvant. To determine the
protective efficacy of GcfDCys4, we examined the lung of
immune mice for viral replication after challenge with live RSV.
Four weeks after the boost immunization, mice were challenged
intranasally with live RSV. As shown in Fig. 7B, there was
active RSV replication in the lung of the PBS immunized mice
and GcfDCys4 immunized mice. Our results indicate that
protective immunity of Gcf requires the conserved cysteine
residues.
Figure 2. Characterization of humoral responses induced by Gcf immunization. (A) BALB/c mice were immunized twice on day 0 and day
14 with 20 mg of recombinant Gcf via indicated routes and serum IgG antibody titers specific for Gcf were measured by ELISA two weeks after the first
and second immunizations. The results represent Log2 endpoint values from individual mice (n=6). The results are a representative of three
independent experiments. (B) Absorbances for RSV-specific IgA were measured in the BAL fluid three weeks after the second immunization. N.D., not
detected.
doi:10.1371/journal.pone.0032226.g002
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injection, or 1610
5 PFU of live RSV A2 via i.n. route, and then challenged with RSV three weeks after final immunization. Lung mononuclear cells were
prepared from the lungs of the same group of mice (n=6) four days after challenge and then stimulated with G(183–195) peptide in the presence of
Brefeldin A. Cells were stained for CD4, CD44, and IFN-c, and analyzed by flow cytometry. Cells gated for CD4 expression are shown in each dot plot
and the percentages represent the frequency of G-specific IFN-c-positive cells The numbers in the upper right quadrant indicate the percentage of
IFN-c+ cells among total lung CD4+ cells after subtracting the percentages by isotype control staining of the same samples. (B) Average data
represent mean 6 SD (n=6). The results are a representative of two independent experiments. (C) Cytokine levels in the lung supernatant were
assessed at day 5 post-challenge by multiplex antibody-based assay (FlowCytomix).
doi:10.1371/journal.pone.0032226.g003
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RSV vaccine has been sought since the virus was discovered in
the 1950s. Due to its tremendous disease burden and the limited
availability of possible prophylactic methods, the need for a safe
and effective RSV vaccine is greater than ever. However, many
hurdles have hampered the development of RSV vaccine: (i) The
higher standards for safety are applied due to possible vaccine-
enhanced immunopathology and the relatively immature state of
young vacinees, (ii) high prevalence of maternal antibodies might
diminish the efficacy of some vaccine candidates like live-
attenuated virus, and (iii) frequent reinfection with the same virus
might be related to short term memory and possible immunoreg-
ulatory mechanisms exerted by RSV. Though various strategies
have been employed to develop RSV vaccine, our aim in the
current study is to develop mucosal RSV vaccine candidates that
are safe and effective. In addition to the superior ability of mucosal
vaccination to induce local mucosal immunity compared to
systemic vaccination, mucosal vaccination also offers many
additional advantages such as a needle-free, non-invasive applica-
tion and convenient delivery without special training. Thus, we
adopted mucosal administration of our vaccine candidate through
the intranasal or sublingual route, which efficiently elicited
respiratory tract immunity.
Our study indicates that sublingual immunization and intrana-
sal immunization of RSV G protein fragment effectively induce
both mucosal and systemic antibody immunity. Also, administra-
tion of recombinant Gcf protein in the absence of any adjuvant is
sufficient to induce humoral responses that provide partial but
potent protection against live virus challenge. Due to a certain
degree of mucosal compartmentalization, the intranasal route for
the delivery of vaccines against respiratory pathogens is thought to
be the most effective for induction of protective mucosal
immunity. However, there has been a safety concern in intranasal
administration due to retrograde passage of delivered antigen/
adjuvant materials through the olfactory epithelium [25,26]. In
contrast to the intranasal route, sublingual administration did not
result in such retrograde passage of vaccines to the central nervous
system [17]. In this regard, sublingual immunization of our Gcf
vaccine might be a safer choice for delivery of RSV vaccine and
our findings provide a rationale for further development of
sublingual Gcf vaccination. More importantly, Gcf vaccination
induced this protective immunity without use of adjuvant.
Normally, protein antigens without adjuvant administered via
the mucosal route are reported to be only weakly immunogenic or
tolerogenic [27], and thus require a mucosal adjuvant such as
cholera toxin (CT) to induce antigen-specific response. Thus,
Figure 4. Low lung eosinophilia in Gcf-immune mice. (A) Mice were immunized and challenged as in Fig. 3. BAL was performed five days after
RSV challenge, and cell pellets were surface stained with anti-CD45, Siglec-F, and CD11c and eosinophils were quantitated among CD45-positive-
gated cells. The numbers in the upper right quadrant indicate the percentage of Siglec-F+CD11c- cells among total CD45+ cells. (B) Average data
represent mean 6 SD (n=6). The results are a representative of three independent experiments.
doi:10.1371/journal.pone.0032226.g004
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advantage in the future development, because most adjuvants
used in vaccines cause unwanted side effects in human.
We targeted the most conserved region of the G protein which
contains several neutralizing epitopes and an important structural
motif. Within the central conserved domain, 13 residues (amino
acids 164 to 176) and four cysteine residues (Cys-173, Cys-176,
Cys-182, Cys-186) are completely conserved among HRSV-A
strains. The secondary structure of this central domain is thought
to be a tight turn, and disulfide bridges could occur between Cys-
173 and Cys-186, and between Cys-176 and Cys-183 [28]. Five
protective B-cell epitopes were identified within this conserved
region of G protein, that were recognized by human sera as well as
by murine mAb [29]. Previously, vaccination of bacterially
Figure 6. Chemotactic activity mediated by Gcf. (A) In vitro chemotaxis was analyzed using transwell insert plate with 5 mm pore size. 10 mgo f
Gcf or GcfDCys4 were added to the bottom chamber and 5610
5 THP-1 cells were added to the top chamber of the plate. Media alone or media with
10% FBS was added as negative or positive control, respectively. The assembled plates were incubated at 37uC for 5 h. Cells migrated to the bottom
chamber were collected and counted at least 3 times. Data are expressed as mean 6 SEM percentages of migrated cells over negative control (media
alone) from at least three independent experiments. (B) In vivo chemotaxis was examined by intranasal administration of Gcf or GcfDCys4 in the
absence of adjuvant and flow cytometric analysis of BAL cells collected 48 h after injection. BAL cells were pooled from at least three mice for each
group and the percentages of cells were calculated after gating viable cells on FSC/SSC.
doi:10.1371/journal.pone.0032226.g006
Figure 5. Protective efficacy of mucosal vaccination with Gcf. Each group of immune mice was challenged with 1610
6 PFU RSV A2 at 4
weeks after immunization and the levels of RSV replication in the lungs were determined by plaque assay at day 4 post challenge. Results are
expressed as the mean 6 SEM (n=6). The limit of detection was 200 PFU/gram of lungs. N.D., not detected.
doi:10.1371/journal.pone.0032226.g005
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130 to 230 of RSV A2 G protein successfully induced protective
immunity against homologous virus challenge [30]. This protein
vaccine also induced cross-protective immunity against RSV B
infection, although the duration of protection was relatively
shorter than that for RSV A virus [31]. In contrast, subgroup-
specific native G proteins did not induce significant cross-
protective immunity [32]. A possible explanation for the cross-
protective immunity induced by the bacterially expressed vaccine
is that the absence of glycosylation increases the immunogenicity
of one or more of the five protective epitopes, which are mostly
conserved between two subgroups. Thus, vaccination of bacterially
expressed Gcf may provide broader than expected cross-
protection against a wide range of RSV strains. This possibility
is under investigation using clinical isolates belonging to the B
subgroup.
Our study clearly demonstrated that Gcf exhibits chemotactic
activity both in vitro and in vivo. The phenotypes of cells recruited
by Gcf administration were CD11c
hi, CD11b
hi, and CD3
+ cells,
which are all known to express CX3CR1 [33,34,35]. Thus, it is
likely that self-adjuvanting effect of Gcf is associated with active
recruitment of antigen-presenting immune cells through CX3C-
CX3CR1 interaction. Several features of G protein have marked
similarities to the CX3C chemokine, fractalkine: the conserved
CX3C motif region of G protein has high homology with the
chemokine domain of fractalkine (,40%), both G protein and
fractalkine exist as membrane-bound and secreted forms, and both
proteins have heparin-binding domains that bind to glycosamino-
glycans on the cell surface [36,37]. Indeed, it has been previously
shown that G protein interacts with CX3CR1 in a manner similar
to fractalkine, suggesting that G protein may modulate the
immune response [6]. While the central CX3C region seems to be
implicated in disease pathogenesis, the same region may also
contribute to the induction of protective immunity by blocking G
protein-CX3CR1 interaction during the course of RSV infection
[38]. In our study, the humoral immunity raised by Gcf
vaccination conferred protection against RSV infection, support-
ing the protective role of antibodies to this region of G protein.
Interestingly, the previous studies have shown that intranasal
immunization of G128–229 elicited poorly immunogenic and
partially protective responses without adjuvant [39]. Our results,
however, differ from this study on several aspects: mucosal
immunization of our Gcf vaccine expressing soluble form of
G131–230 elicited serum IgG and RSV-specific CD4 T-cell
response, which led to protective immunity in BALB/c mice
without adjuvant. We think that poorly immunogenic responses of
G128–229 immunization might be due to fusion with bacterial
thioredoxin, which might affect the conformation of G fragment.
The similar region of G (130–230) had previously been reported in
bacteria as a fusion with the albumin-binding region of
streptococcal protein G [30]. It also induced poorly humoral
immune responses without adjuvant. Relatively strong immuno-
genicity of Gcf may be due to expression of soluble Gcf by itself,
and soluble Gcf configuration without any fusion partner may be
important for effective self-adjuvanticity by chemotaxis and
subsequent activation of immune cells. However, we cannot
exclude the possibility that the several experimental conditions like
injection volume, the amount of administered antigen, and the
buffer composition are different from each other and these make it
difficult to interpret and directly compare those results and ours.
Based on our results, we believe that native Gcf conformation
without carrier protein is more effective in inducing the immune
responses in the absence of adjuvant. Further study might be
necessary to elucidate the mechanisms of this difference.
In conclusion, we demonstrate that procaryotically expressed G
protein fragment, Gcf, is a promising candidate for mucosal RSV
vaccine and potent protective immunity could be induced by
sublingual or intranasal administration even in the absence of
adjuvant. Our study also clearly demonstrated that the cysteine
residues and chemotactic activity are necessary for the induction of
specific immunity by Gcf in the absence of adjuvant, proposing a
novel self-adjuvanticity of Gcf. Further study is necessary to
Figure 7. Cysteine residues of Gcf are necessary for the induction of specific antibody response and protection. (A) BALB/c mice were
immunized twice with 20 mg of recombinant Gcf or mutant GcfDCys4 via intranasal route and specific serum antibody titers were measured by ELISA
two weeks after immunization. The results represent Log2 endpoint values from at least five individual mice. (B) Each group of i.n. immunized mice
was challenged with 2610
6 PFU RSV A2 at 4 weeks after boost immunization and the levels of RSV replication in the lungs were determined by
plaque assay at day 5 post challenge. Results are expressed as the mean 6 SEM (n=6). The limit of detection was 200 PFU/gram of lungs.
doi:10.1371/journal.pone.0032226.g007
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property of Gcf mucosal vaccine and to develop Gcf as a mucosal
vaccine for human use.
Materials and Methods
Ethics statement
All animal experiments were also approved by Ewha Womans
University’s Institutional Animal Care and Use Committee
(Approval ID: 2010-9-4).
Preparation of RSV stock
RSV A2 strain was propagated in HEp-2 cells (ATCC,
Manassas, VA) in DMEM (Life Technologies, Gaithersburg,
MD) supplemented with 3% heat-inactivated FCS, 2 mM
glutamine, 20 mM HEPES, nonessential amino acids, penicillin,
and streptomycin. Virus was harvested at day 4,5 after infection
when the infected HEp-2 cells exhibited maximal cytopathic
effect. In brief, cells were disrupted by three cycles of freeze-
thawing, then sonicated for 1 min, and centrifuged at 300 g for
10 min. The supernatants were collected, combined with cleared
supernatants from the infected HEp-2 culture, and centrifuged at
75,000 g for 1 hour. The pellets were resuspended with serum-free
MEM by using 25-gauge needle and brief sonication, and the final
titer was determined by standard plaque assay.
Construction of expression vectors and purification of
RSV G protein fragment
The coding sequence of RSV G protein spanning from amino
acid residues 131 to 230 (RSV A2 strain) was amplified from
cDNA by PCR and cloned into the EcoR I and Hind III sites of
pET-21d(+) vector (Novagen). A mutant DNA in which four
cysteine residues (Cys-172, Cys-176, Cys-182, Cys-186) were
substituted with alanine was generated by mega-PCR method with
mutagenic primers [40]. The constructed plasmid was transformed
into E. coli BL21(DE3) (Novagen) and overexpression was induced
by adding Isopropyl b-D-1-thiogalactopyranoside (IPTG, Takara,
Shiga, Japan). After centrifugation, bacterial cells were suspended
in binding buffer (20 mM Tris, 0.5 M NaCl, pH 8.0) and
sonicated. Soluble and insoluble proteins were separated by
centrifugation at 40,0006g for 20 min and clear supernatants
were used for further purification. Expressed G protein fragment
(Gcf) and mutant Gcf (GcfDCys4) were purified by affinity
chromatography using HisTrap column (GE Healthcare). After
washing with binding buffer containing 20 mM imidazole, loaded
proteins were eluted with elution buffer (500 mM imidazole,
20 mM Tris, 0.5 M NaCl, pH 7.4). Eluted protein fractions were
further purified using Superdex-75 column after equilibration with
PBS (GE Healthcare). The purified protein was treated with 1%
Triton X-114 to remove endotoxins for 30 min at 4uC, followed
by incubation at 37uC for 20 min. The phase containing
endotoxin was separated by centrifugation. This cycle was
repeated five times. Then, the protein was incubated with SM-2
beads (Bio-Rad, Hercules, CA) for 2 h at 4uC to remove residual
Triton X-114 and filtered through spin-X column (Costar,
Washington, DC). The endotoxin levels in the protein preparation
were measured by the limulus amebocyte lysate (LAL) assay kit
according to the manufacturer’s instructions (Lonza, Switzerland).
The endotoxin level was less than 5 EU/mg. Protein concentra-
tions were measured by Bio-Rad Protein assay (Bio-Rad
Laboratories). The centrifugal filter, AmiconH ultra (Millipore,
Bedford, MA) was used for additional concentration. To visualize
the purification, samples were resolved on 15% SDS-PAGE and
stained with Coomassie Brilliant Blue. The purity of Gcf vaccine
was also verified by western blotting using RSV-specific goat
polyclonal antibody (US Biological) and HRP-conjugated anti-
goat Ig antibody (Zymed Laboratories, San Francisco, CA).
Purified proteins were stored at 280uC in aliquots until use.
Mice immunization and challenge
Female BALB/c mice were purchased from Charles River
Laboratories Inc. (Yokohama, Japan) and kept under specific
pathogen-free conditions. For the immunization, 6 to 8-week-old
mice were inoculated twice on day 0 and day 14 with 20 mgo f
purified G protein fragment via the sublingual (s.l.) or intranasal
(i.n.) route. For s.l. immunization, mice were anesthetized by i.p.
injection of ketamine and recombinant RSV G fragment with or
without cholera toxin (2 mg) in 15 ml were delivered underneath
the tongue. For i.n. immunization, mice were lightly anesthetized
by isoflurane inhalation, and 50 ml of vaccine or PBS were applied
to the left nostril. FI-RSV (1610
5 PFU in 50 ml) with aluminum
hydroxide (Sigma-Aldrich, Seoul, Korea) was administered once
through the foot pad of anesthetized mice. As a positive control,
live RSV (1610
5 PFU) was i.n. delivered once. Three to four
weeks after the last immunization, the mice were challenged i.n.
with 1610
6 or 2610
6 PFU of live RSV A2, if necessary. All
animal studies were performed with approval of our Institutional
Animal Care and Use Committee (Approval No. 2010-9-4).
ELISA
Blood was obtained from the retro-orbital plexus via a
heparinized capillary tube, collected in an eppendorf tube and
centrifuged; serum was obtained and stored at 220uC. Antibody
titers from immunized mice specific for RSV G protein were
measured by direct ELISA. Briefly, 96-well plates were coated
overnight with 100 ml/well of 2610
3 PFU of purified RSV A2
virus diluted in PBS, and blocked with PBS containing 2% BSA
and 0.05% Tween 20 for 2 h. Sera or BAL fluids were then added
in serial dilutions and incubated for 2 h. The plates were washed
five times with PBS containing 0.05% Tween 20 and incubated for
1 h with varying dilutions of HRP-conjugated affinity-purified
rabbit anti-mouse total IgG or IgA secondary antibody (Zymed
Laboratories, San Francisco, CA). The plates were washed three
times, developed with 3,39,5,59-tetramethylbenzidine, stopped
with 1M H3PO4, and analyzed at 450 nm by a Thermo ELISA
plate reader. Naı ¨ve pooled sera from age-matched mice were used
as a negative reference sera and if OD differences of the samples to
the negative reference at the same dilution were not greater than
0.1, these values were regarded as ‘not detected’. Cut-off points
were calculated by subtracting the background values of the
negative reference from those of experimental samples at the same
dilutions and subsequent linear regression analysis.
RSV titer in the lung
Four days after RSV challenge, subsets of mice were euthanized
and the lungs were removed into Eagle’s modified essential
medium. The tissues were then processed through a steel screen to
obtain single-cell suspensions, and particulate matter was removed
by passing through 70-mm cell strainer (BD Labware, Franklin
Lakes, NJ). The supernatants were collected and RSV titers in the
supernatants were measured by plaque assay on subconfluent
HEp-2 monolayers. The data are expressed as PFU per gram of
lung tissue.
Bronchoalveolar lavage (BAL)
Five days post challenge, a subset of mice from each group was
sacrificed and tracheotomy was performed. The lung airways were
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BAL cells and supernatants were used in counting leukocytes by
flow cytometry and measuring secretory IgA titers, respectively.
Preparation of lung lymphocytes and flow cytometric
analysis
The lungs were perfused with 5 ml of PBS containing 10 U/ml
heparin, and then removed and processed through a steel screen to
obtain single-cell suspensions; particulate matter was removed by
passage through 70-mm Falcon cell strainer (BD Labware). Freshly
explanted BAL or lung cells were purified by density gradient
centrifugation and were stained in a buffer (PBS/3% FBS/0.09%
NaN3) with fluorochrome-conjugated antibodies. The antibodies
used were anti-CD3e (clone 145-2C11), anti-CD4 (RM4-5), anti-
CD11b (M1/70), anti-CD11c (HL3), anti-CD14 (rmC5-3), anti-
CD44 (IM7), anti-CD80 (16-10A1), and anti-Siglec F (E50–2440).
All antibodies were purchased from BD Bioscience (San Diego,
CA). After staining, cells were fixed in PBS/2% (wt/vol)
paraformaldehyde, and events were acquired using a FACSCali-
burH flow cytometer (BD Biosciences). To enumerate the cytokine-
producing cells, cells were stimulated with 10 mM G(183–195)
peptide (WAICKRIPNKKPG), and incubated for 5 h in the
presence of Brefeldin A (5 mg/ml; Sigma-Aldrich). Then, cells
were stained for surface markers, washed, fixed and permeabilized
with FACS buffer containing 0.5% saponin (Sigma-Aldrich), and
stained for IFN-c. The antibodies used were anti-IFN-c (clone
XMG1.2) or its control isotype antibody (rat IgG1). Dead cells
were excluded on the basis of forward and side light scatter
patterns. Data were collected using CELLQuestH software (BD
Biosciences) and analyzed with CELLQuestH and WinMDI
version 2.9 software (The Scripps Research Institute, La Jolla,
CA). Lung supernatants were collected for analysis with the
FlowCytomix (eBioscience), according to the protocol. Kits
containing antibody beads (IL-4, IL-5, IL-6, IL-10, IL-13) were
used to measure cytokine production in each of the samples.
Chemotaxis assay
Chemotaxis was analyzed using 24-well tissue-culture-treated
transwell insert plate with 5 mm pore size (Costar, Corning, NY).
10 mg of Gcf or GcfDCys4 in DMEM with 1% BSA were added to
the bottom chamber and a total of 5610
5 THP-1 cells, human
monocyte leukemia cell line, were added to the top chamber of the
plate. The assembled plates were incubated at 37uC for 5 h. Cells
migrated to the bottom chamber were collected and counted in a
blinded manner. Experiments were performed in triplicate and
counts represent an average of three replicates. The experiment
was repeated three times and the data were averaged.
Data analysis
The differences were compared by an unpaired, two-tailed
Student’s t-test. The difference was considered statistically
significant when p value #0.05.
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